A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED FOR 6 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and PF 06865571 along with the effects on selected pharmacodynamics (PD)/exploratory parameters, compared to administration of PF 05221304 alone, PF 06865571 alone, and placebo in adults with NAFLD.

Study Overview

• Status: Completed
• Conditions: Non-Alcoholic Fatty Liver Disease (NAFLD)
• Intervention / Treatment: Drug: Placebo; Drug: PF-05221304 Monotherapy; Drug: PF-06865571 Monotherapy; Drug: PF-05221304 and PF-06865571 Combination

• Study Type: Interventional
• Enrollment (Actual): 99
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Bakersfield, California, United States, 93301
      • Franco Felizarta, MD
    • Beverly Hills, California, United States, 90211
      • Westside Medical Associates of Los Angeles
    • Chula Vista, California, United States, 91911
      • ProSciento, Inc.
    • Los Angeles, California, United States, 90057
      • National Research Institute - Wilshire
    • Montclair, California, United States, 91763
      • Catalina Research Institute, LLC
  • Florida
    • Hialeah, Florida, United States, 33016
      • Floridian Clinical Research, LLC
    • Hollywood, Florida, United States, 33024
      • Research Centers of America, LLC
    • Jacksonville, Florida, United States, 32216
      • Jacksonville Center for Clinical Research
    • Miami, Florida, United States, 33126
      • Pharmax Research Clinic
    • Orlando, Florida, United States, 32810
      • Omega Research Maitland
    • Orlando, Florida, United States, 32819
      • Accel Research Sites
    • Palm Harbor, Florida, United States, 34684
      • Advanced Gastroenterology Associates, LLC
    • South Miami, Florida, United States, 33143
      • QPS-MRA, LLC-Main Office
  • Hawaii
    • Honolulu, Hawaii, United States, 96814
      • East-West Medical Research Institute
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • Midwest Institute for Clinical Research
  • Kansas
    • Wichita, Kansas, United States, 67207
      • Heartland Research Associates, LLC
  • Kentucky
    • Louisville, Kentucky, United States, 40213
      • L-MARC Research Center
  • New York
    • East Syracuse, New York, United States, 13057
      • Clarity Clinical Research
  • North Carolina
    • High Point, North Carolina, United States, 27265
      • High Point Clinical Trials Center
    • Raleigh, North Carolina, United States, 27612
      • M3 Wake Research, Inc
    • Raleigh, North Carolina, United States, 27612
      • Wake Gastroenterology
    • Wilmington, North Carolina, United States, 28401
      • PMG Research of Wilmington, LLC
  • Ohio
    • Cincinnati, Ohio, United States, 45242
      • New Horizons Clinical Research
    • Cincinnati, Ohio, United States, 45219
      • Sterling Research Group - Mt. Auburn
  • Tennessee
    • Chattanooga, Tennessee, United States, 37421
      • WR-Clinsearch, LLC
    • Knoxville, Tennessee, United States, 37920
      • New Orleans Center for Clinical Research
    • Knoxville, Tennessee, United States, 37920
      • University of Tennessee Medical Center - Radiology
  • Texas
    • San Antonio, Texas, United States, 78229
      • Clinical Trials of Texas, Inc.
  • Virginia
    • Richmond, Virginia, United States, 23294
      • National Clinical Research-Richmond, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male subjects or female subjects of non childbearing potential
• Total body weight of >50 kg (110 lbs) and a BMI greater than or equal to 25 kg/m2

• Medical diagnosis of Type 2 Diabetes Mellitus (T2DM) being treated with no more than 1 acceptable oral antidiabetic drug OR Subjects without a diagnosis of T2DM that meet 2 or more of the following 5 criteria commonly associated with metabolic syndrome

  • Fasting Plasma Glucose (FPG) greater than or equal to 100 mg/dL;
  • Documentation of at least stage 1 hypertension or medical history of hypertension;
  • Fasting serum HDL C <40 mg/dL for males and <50 mg/dL for females, or on pharmacological agents with explicit purpose to increase HDL-C;
  • Fasting serum triglyceride (TG) greater than or equal to 150 mg/dL or on pharmacological agents with explicit purpose to decrease TG;
  • Waist circumference greater than or equal to 40 inches (102 cm) for males and 35 inches (89 cm) for females.
• Liver fat greater than or equal to 8% measured by MRI PDFF

Exclusion Criteria:

• Subjects with acute or chronic medical or psychiatric condition.

• Subjects with any of the following clinical laboratory abnormalities:

  • Fasting TG >400 mg/dL;
  • AST, ALT, or GGT >2.0x ULN;
  • Hemoglobin A1c (HbA1c) >7.0%;
  • Fasting plasma glucose >270 mg/dL;
  • Total bilirubin >1.5x ULN;
  • Albumin < lower limit of normal (LLN);
  • Platelet count <0.95x LLN;
  • International normalized ratio (INR) greater than or equal to 1.3.
• A positive urine test for illicit drugs.
• History of regular alcohol consumption.
• Seated systolic BP>=160 mmHg and/or diastolic BP>=100 mmHg.
• Supine 12 lead ECG demonstrating a corrected QT (QTcF) interval >450 msec or a QRS interval >120 msec.
• Subjects with an estimated GFR <60 mL/min/1.73m2.
• Evidence or diagnosis of other forms of chronic liver diseases.

• Subjects with any of the following medical conditions:

  • Any condition possibly affecting drug absorption (eg prior bariatric surgery, gastrectomy, ileal resection);
  • Diagnosis of type 1 diabetes mellitus;
  • History of congestive heart failure, unstable angina, myocardial infarction, stroke, or transient ischemic attack;
  • Any malignancy not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin);
  • Active placement of medical devices in/on thoracic or abdominal cavities such as pacemakers, defibrillators;
• Subjects with any anatomical or pathological abnormality that would either preclude or tend to confound the analysis of study data.
• Blood donation of approximately 1 pint or more within 60 days prior to dosing.
• Subjects taking prohibited concomitant medication(s) or those unwilling/unable to switch to permitted concomitant medication(s)
• Weight loss of greater than or equal to 5% within 1 month prior to Screening.
• Unwilling or unable to comply with the Lifestyle Requirements criteria of the protocol.
• Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential; fertile male subjects who are unwilling or unable to use highly effective method(s) of contraception.
• Investigator site staff members or Pfizer employees, including their family members, directly involved in the conduct of the study.
• Subjects with known prior treatment with or participation in a clinical trial involving any of the IPs

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo; Placebo (PF 05221304) BID Placebo (PF 06865571) BID	Drug: Placebo; Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm A
EXPERIMENTAL: PF-05221304 Monotherapy; 15 mg PF-05221304 BID Placebo (PF-06865571) BID	Drug: Placebo; Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm A; Drug: PF-05221304 Monotherapy; Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm B
EXPERIMENTAL: PF-06865571 Monotherapy; Placebo (PF-05221304) BID 300 mg PF-06865571 BID	Drug: Placebo; Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm A; Drug: PF-06865571 Monotherapy; Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm C
EXPERIMENTAL: PF-05221304 and PF-06865571 Combination; 15 mg PF-05221304 BID 300 mg PF-06865571 BID	Drug: PF-05221304 Monotherapy; Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm B; Drug: PF-06865571 Monotherapy; Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm C; Drug: PF-05221304 and PF-06865571 Combination; Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.; Other Names: Arm D

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42	Magnetic resonance imaging proton density fat fraction (MRI-PDFF) technique is an established method that enables quantification of fat content in the liver. It measures the fraction of mobile protons in the liver attributable to fat content and provides whole liver coverage so that fat content can be assessed across 8 Couinaud liver segments. Whole liver PDFF = PDFFs for (Segment I + Segment II + Segment III + Segment IVa + Segment IVb + Segment V + Segment VI + Segment VII + Segment VIII) divided by total number of segments assessed.	Baseline, Day 42

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included all serious and non-serious adverse events.	Baseline up to 35 days from last dose of study drug or early termination: (maximum up to Day 77)
Number of Participants With Laboratory Abnormalities	Clinical chemistry: Bilirubin (milligram per deciliter [mg/dL]), direct bilirubin (mg/dL)>3.0*upper limit of normal (ULN), alanine aminotransferase international units per liter (U/L), aspartate aminotransferase (U/L), alkaline phosphatase (U/L), gamma glutamyl transferase (U/L)>5.0*ULN, urea nitrogen (mg/dL)>2.0*ULN, low density lipoprotein direct endpoint measure (mg/dL)>1.5*ULN, triglycerides (mg/dL)>2.0*ULN, creatinine based estimated glomerular filtration rate by modification of diet in renal disease equation and cystatin based eGFR by chronic kidney disease epidemiology collaboration equation (C <60 milliliter per minute per 1.73 square of meter), very low density lipoprotein (millimoles per liter), Cholesterol >2.0*ULN.	Baseline up to 35 days last from dose of study drug or early termination (maximum up to Day 77)
Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Blood Pressure	Vital signs included systolic blood pressure, diastolic blood pressure and pulse rate.	Baseline, Post-last dose of study drug (up to Day 42)
Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Pulse Rate	Vital signs included systolic blood pressure, diastolic blood pressure and pulse rate.	Baseline, Post- last dose of study drug (up to Day 42)
Number of Participants Meeting Pre-Specified Electrocardiogram (ECG) Criteria	ECG criteria included: 1) PR interval (milliseconds [msec]): baseline greater than (>) 200 msec and maximum increase from baseline greater than or equal to (>=) 25 percent (%) or baseline less than or equal to (<=) 200 msec and maximum increase from baseline >=50%; 2) QRS interval (msec): maximum increase from baseline >=50%; 3) QT interval corrected using Fridericia's formula (QTcF): a) change from baseline >30 msec and <=60 msec, b) change from baseline >60 msec.	Baseline up to 35 days last dose of study drug or early termination (maximum up to Day 77)

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

General Publications

• Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, Aggarwal S, Crowley C, Rinaldi A, Mancuso J, Aggarwal N, Somayaji V, Inglot M, Tuthill TA, Kou K, Boucher M, Tesz G, Dullea R, Bence KK, Kim AM, Pfefferkorn JA, Esler WP. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nat Med. 2021 Oct;27(10):1836-1848. doi: 10.1038/s41591-021-01489-1. Epub 2021 Oct 11.

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 4, 2019
• Primary Completion (ACTUAL): September 9, 2019
• Study Completion (ACTUAL): October 11, 2019

Study Registration Dates

• First Submitted: December 12, 2018
• First Submitted That Met QC Criteria: December 12, 2018
• First Posted (ACTUAL): December 14, 2018

Study Record Updates

• Last Update Posted (ACTUAL): September 23, 2020
• Last Update Submitted That Met QC Criteria: September 2, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease
• Other Study ID Numbers: C3711001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No